Topical lomustine in the treatment of psoriasis.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001772:Blood Cell Count; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003877:Dermatitis, Contact / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010859:Pigmentation Disorders / Q000150:complications; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000150:complications; D014508:Urea / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D014508:Urea